PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.95%
ROE 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 0.76%. Mohnish Pabrai would see if this premium is justified by consistent earnings.
0.68%
ROA of 0.68% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
0.17%
ROCE of 0.17% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
36.02%
Gross margin 50-75% of Drug Manufacturers - Specialty & Generic median of 55.21%. Guy Spier would question if commodity-like dynamics exist.
3.17%
Margin of 3.17% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
13.04%
Net margin of 13.04% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.